ENZAMET Update Confirms OS Benefit With Enzalutamide in Metastatic Hormone-Sensitive Prostate Cancer
Doublet therapy is here to stay for mHSPC – updated OS presented from ENZAMET.
Related Articles
Women with heart disease are less likely to receive life-saving drugs than men
Read the full article here
Age-Related Hearing Loss | NEJM
Hearing progressively declines with age, manifesting initially as difficulty understanding speech in background noise and detrimentally affecting social functioning. Strategies and technologies can…
Registration Options – AUA Annual Meeting
Registration options for virtual and in-person options for AUA2024 in San Antonio, TX.
Tetrapodal textured Janus textiles for accessible menstrual health
Materials science; Materials chemistry; Materials synthesis
2024 #RAREis Global Advocate Grant
A program by Amgen to support and empower the rare disease community around the world. As part of our mission, we strive to improve the…
Why Publish
Why submit to an official British Society for Rheumatology journal? Rheumatology Advances in Practice Rheumatology Advances in Practice is an
Cigna Group Foundation unveils grant program targeting youth mental health
Cigna has announced a new multiyear initiative that aims to invest in improving youth mental health. | Cigna has announced a new multiyear initiative that…
A Pilot Randomized Trial Evaluating the Cool 2 Be Safe Junior Playground Safety Program for Preschool Children
AbstractObjective. Unintentional injury is the leading cause of death to children worldwide, and playgrounds pose a significant risk of injury. Those aged
Evaluation of Antioxidants’ Ability to Enhance Hyaluronic-acid Based Topical Moisturizers | JCAD | The Journal of Clinical and Aesthetic Dermatology
J Clin Aesthet Dermatol. 2024;17(3):48–51. by Joshua Zeichner, MD; Edward (Ted) Lain, MD, MBA; Kavita Mariwalla, MD; Tanja Bußmann, Dr; Julia M. Weise, Dr; Elisabeth Maaß;…
In chronic coronary syndrome, women less likely to get cholesterol-lowering drugs vs. men
Among patients with chronic coronary syndrome, women were less likely than men to be treated with lipid-lowering therapy, researchers reported at ESC Preventive Cardiology 2024.Women…
